Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,302 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07500701RecruitingPhase 3
Comparing two radiation schedules for rising PSA after prostate surgery
This trial is testing two types of radiation therapy for men whose PSA level rises after prostate removal, but without clear signs of cancer spread on a PSMA PET scan. The goal is to see which radiation schedule works better to control the cancer.
Seoul, Gangnam-guAges 20 years+ - NCT07504796RecruitingPhase 2
Adding ipilimumab to standard melanoma therapy based on ctDNA
This trial tests whether adding a second immunotherapy drug (ipilimumab) to the standard first-line combo of nivolumab and relatlimab improves outcomes for advanced melanoma. It uses a blood test (ctDNA) to decide who gets the extra drug.
New York, New YorkAges 18 years+ - NCT04615143RecruitingPhase 2
Tislelizumab with or without lenvatinib before liver surgery
This trial studies whether taking tislelizumab alone or with lenvatinib before surgery can shrink recurrent liver cancer and improve outcomes. It may help by treating the cancer earlier (before the tumor is removed).
Guangzhou, GuangdongAges 18–75 - NCT06767254Recruiting
Using AI to predict early return of multiple myeloma
This study uses artificial intelligence to analyze how multiple myeloma may lead to early relapse. It may help doctors better predict and manage the disease.
Meldola, Forlì-CesenaAges 18 years+ - NCT06664021RecruitingPhase 2
Tislelizumab and S-1 for recurrent high-risk bile duct cancer
This trial tests a combination of two drugs (tislelizumab and S-1) for people whose bile duct cancer has come back after surgery and had high-risk features. The goal is to see if this treatment can help control the cancer.
Fuyang, AnhuiAges 18–75 - NCT06492005RecruitingPhase 2
Study of 9MW2821 for advanced triple-negative breast cancer
This trial tests a new drug, 9MW2821 (sometimes with a PD-1 inhibitor), for people with advanced triple-negative breast cancer. It may be an option if you've already tried standard treatments or haven't started any yet.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06572813RecruitingPhase 1/Phase 2
Combination therapy for advanced pancreatic cancer
This trial tests whether adding bortezomib and an immunotherapy drug to standard chemotherapy can help people with pancreatic cancer that has spread to other organs. It is for patients who have not had treatment or whose cancer has worsened after gemcitabine-based chemotherapy.
Hangzhou, ZhejiangAges 18–75 - NCT07493928Recruiting
HPV testing after chemoradiation for cervical cancer
This trial checks if HPV is still present after standard radiation and chemo for cervical cancer. It may help see how well the treatment worked.
PragueAges 18 years+ - NCT07495124RecruitingPhase 2
IGFBP-2 vaccine to prevent ovarian cancer return
This trial tests a vaccine that targets a protein called IGFBP-2 to prevent ovarian cancer from coming back. It is for people whose CA-125 blood test shows the cancer might be returning, but who don't yet have tumors visible on scans.
Seattle, WashingtonAges 18 years+ - NCT07492628RecruitingPhase 1
Dual-target cell therapy for advanced bladder cancer
This trial tests a new treatment that uses your own immune cells, called CAR-NK cells, modified to attack two proteins (Nectin-4 and HER2) often found on bladder cancer cells. It is for people whose cancer has spread or cannot be removed by surgery and has not responded to standard treatments like chemotherapy or immunotherapy.
Shenzhen, GuangdongAges 18–75 - NCT06622031Recruiting
TIPS with lenvatinib and immunotherapy for advanced liver cancer
This trial combines a procedure called TIPS (which helps relieve pressure in the liver) with two drugs—lenvatinib (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—for people with advanced liver cancer that has spread into the main vein of the liver. It aims to see if this combination can help control the cancer and improve symptoms.
Beijing, None SelectedAges 18–75 - NCT07480928RecruitingPhase 1/Phase 2
CAR-NK cell therapy for advanced pancreatic cancer
This trial tests a new type of immune cell therapy called CAR-NK cells that target two proteins (MSLN and MUC1) often found on pancreatic cancer cells. It is for people whose cancer has spread or cannot be removed, and who have already tried at least one standard treatment.
Shenzhen, GuangdongAges 18–75 - NCT07487350Recruiting
Recurrent leishmaniasis in people with HIV
This study looks at better ways to treat visceral leishmaniasis (a serious parasitic infection) when it comes back in people who also have HIV. It may help find a plan that works longer and reduces the chance of relapse.
GonderAges 18 years+ - NCT07483853Recruiting
MRI scoring test for chronic bone inflammation in children
This study checks if a new MRI scoring system can reliably measure bone inflammation in children with a rare bone disease called CRMO. The goal is to improve how doctors monitor the disease.
BolognaAges Up to 32 years - NCT07485686Enrolling by invitation
Studying urinary tract infections to improve treatment
This study collects medical data from people with urinary tract infections (UTIs) to help future research and improve how UTIs are treated. You may be eligible if you have symptoms of a UTI now or have had them in the past.
FrankfurtAges 18 years+ - NCT07488039Recruiting
Labral repair for shoulder instability with minor bone loss
This trial tests a surgery to repair a torn shoulder socket rim (labrum) in people with recurrent shoulder dislocations and minor bone loss. It aims to restore shoulder stability and prevent future dislocations.
Cairo, Cairo GovernorateAges 16 years+ - NCT07488949Recruiting
Doxycycline and progestin for chronic endometritis in recurrent pregnancy loss
This trial tests whether combining an antibiotic (doxycycline) with a hormone treatment (progestin) can help people with chronic endometritis—a type of uterine inflammation—who have had repeated miscarriages or failed IVF cycles. The goal is to improve the chance of a successful pregnancy.
Lanzhou, GansuAges 20–45 - NCT06776757RecruitingPhase 1/Phase 2
Sintilimab plus cetuximab and chemo for first-line advanced colorectal cancer
This trial tests a combination of immunotherapy (sintilimab), a targeted therapy (cetuximab), and chemotherapy as a first treatment for advanced colorectal cancer that hasn't spread or come back after earlier treatment. It's for people whose tumors have certain genetic markers (RAS/BRAF wild-type) and show signs of immune activity (PD-L1 or CD8+ TILs).
Shenzhen, GuangdongAges 18–75 - NCT06777017Recruiting
Can liver stiffness predict cancer return after ablation?
This trial studies if measuring liver and spleen stiffness can help predict the risk of liver cancer coming back after radiofrequency ablation (RFA), a treatment that uses heat to destroy tumors. It aims to improve follow-up care for people with chronic liver disease and early-stage liver cancer.
BolognaAges 18 years+ - NCT06778603RecruitingPhase 1/Phase 2
Using B7-H3 imaging to guide osteosarcoma surgery
This trial tests a special dye that targets B7-H3, a protein found on osteosarcoma cells. Before your surgery, the dye is injected and helps surgeons see tumor edges more clearly, so they can remove all of the cancer while saving healthy tissue.
Beijing, Beijing MunicipalityAges 18–60 - NCT07475026RecruitingPhase 3
Combination therapy before surgery for high-risk liver cancer
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
TianjinAges 18–75 - NCT07474090Recruiting
Personalized Exercise Program for Breast Cancer Survivors
This study tests whether a personalized exercise program during chemotherapy helps breast cancer survivors recover better and feel stronger. You'll use a smartphone app to do guided workouts at home while getting support from exercise coaches.
Winston-Salem, North CarolinaAges 18–85 - NCT07477496Recruiting
Anal fistula surgery recovery study
This study follows people having surgery for an anal fistula to see how well they recover. It uses your feedback to measure results, and you'll have check-ins for a year.
AthensAges 18 years+ - NCT07477626RecruitingPhase 3
Radiation therapy after prostate surgery for advanced prostate cancer
This study tests whether radiation therapy to the pelvis after prostate removal helps men whose cancer was found in nearby lymph nodes. The goal is to prevent cancer from coming back and improve survival.
Dongguan, GuangdongAges 18 years+
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,302 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.